Discover undervalued stocks with Eulerpool.

Subscribe for $2

Mesoblast Stock MSB.AX

Price

1.60
Today +/-
+0.02
Today %
+1.49 %

Mesoblast stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Mesoblast stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Mesoblast stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Mesoblast stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Mesoblast's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Mesoblast Stock Price History

DateMesoblast Price
9/29/20251.60 undefined
9/26/20251.57 undefined
9/25/20251.64 undefined
9/24/20251.61 undefined
9/23/20251.64 undefined
9/22/20251.67 undefined
9/19/20251.62 undefined
9/18/20251.55 undefined
9/17/20251.54 undefined
9/16/20251.56 undefined
9/15/20251.54 undefined
9/12/20251.47 undefined
9/11/20251.55 undefined
9/10/20251.54 undefined
9/9/20251.48 undefined
9/8/20251.46 undefined
9/5/20251.40 undefined
9/4/20251.30 undefined
9/3/20251.27 undefined
9/2/20251.31 undefined
9/1/20251.32 undefined

Mesoblast Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Mesoblast, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Mesoblast from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Mesoblast’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Mesoblast. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Mesoblast’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Mesoblast’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Mesoblast’s growth potential.

Mesoblast Revenue, EBIT and net profit per share

DateMesoblast RevenueMesoblast EBITMesoblast Net Income
2031e1.32 B undefined0 undefined0 undefined
2030e805.05 M undefined381.07 M undefined0 undefined
2029e510.34 M undefined191.59 M undefined0 undefined
2028e351.37 M undefined221.92 M undefined422.32 M undefined
2027e182.89 M undefined46.44 M undefined-31.23 M undefined
2026e66.82 M undefined-36.11 M undefined-248.12 M undefined
202517.2 M undefined-82.3 M undefined-102.14 M undefined
20245.9 M undefined-66.89 M undefined-87.96 M undefined
20237.5 M undefined-62.72 M undefined-81.89 M undefined
202210.21 M undefined-73.76 M undefined-91.35 M undefined
20217.46 M undefined-90.39 M undefined-98.81 M undefined
202032.16 M undefined-73.49 M undefined-77.94 M undefined
201916.72 M undefined-86.47 M undefined-89.8 M undefined
201817.34 M undefined-64.31 M undefined-35.29 M undefined
20172.41 M undefined-90.17 M undefined-76.82 M undefined
201642.55 M undefined-18.47 M undefined-4.13 M undefined
201519.76 M undefined-91.79 M undefined-96.24 M undefined
201423.84 M undefined-67.85 M undefined-74.28 M undefined
201329.52 M undefined-61.6 M undefined-63.23 M undefined
201239.34 M undefined-50.24 M undefined-73.36 M undefined
201118.99 M undefined-7.79 M undefined89.36 M undefined
2010660,000 undefined-9.14 M undefined-13.01 M undefined
2009650,000 undefined-6.93 M undefined-9.03 M undefined
2008810,000 undefined-7.1 M undefined-9 M undefined
20071.32 M undefined-5.5 M undefined-6.85 M undefined
20062.11 M undefined-4.7 M undefined-6.2 M undefined

Mesoblast Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (B)
DOCUMENTS
2005200620072008200920102011201220132014201520162017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
0000000.020.040.030.020.020.0400.020.020.030.010.010.010.010.020.070.180.350.510.811.32
---50.00----116.67-25.64-20.69-17.39121.05-95.24750.00-5.88100.00-78.1342.86-30.00-28.57240.00288.24175.7692.8645.3057.8463.98
-600.001,200.00---66.6741.0327.59-4.35-21.0528.57-450.0064.716.2518.75-357.14-200.00-285.71-180.0070.5918.186.593.422.351.490.91
0000000168-1-412-91116-25-20-20-912000000
-1-6-6-9-9-1389-73-63-74-96-4-76-35-89-77-98-91-81-87-102-248-31422000
-500.00-50.00-44.44-784.62-182.02-13.7017.4629.73-95.831,800.00-53.95154.29-13.4827.27-7.14-10.997.4117.24143.14-87.50-1,461.29---
0.070.090.110.120.130.140.230.290.30.320.320.360.40.470.490.530.640.680.780.991.21000000
- - - - - - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Mesoblast Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Mesoblast is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (B)
ADDITIONAL PAID-IN CAPITAL (M)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (k)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
200520062007200820092010201120122013201420152016201720182019202020212022202320242025
                                         
11.55.810.213.513.327.7282.1211.6288.1185.2110.780.9345.5137.6150.03128.93136.3860.0370.9262.56161.16
000.300.10.10.12.2000.140.70.596.711.740.6822.222.281.413.91
000.10.10.10.32.28.7115.83.843.352.943.412.320.92.842.184.7220.96
0000000000000000000022.25
00.100.10.10.10.20.34.11.27.793.8414.6113.348.446.0575.43.7420.56.08
11.55.910.613.713.628.2284.6222.8303.2192.2122.4688.8263.61101.0762.52136.55148.2369.8481.6686.46204.35
000.10.20.20.20.722.54.44.43.061.811.080.8310.2712.149.976.493.845.82
45.66.512.27.54.500002.31.9722.322.321.872.081.761.761.011.39
00000000000001.471.471.4700000
0.50.60.70.50.40.4391.8389.9383.8516.2515.79453.37451.9450.15448.67447.15446.09444.2442.73441.28437.37
000000117.6118.9116.7132.5134.45134.45134.45134.45134.45134.45134.45134.45134.45134.45134.45
00000023.43.61.22.82.372.341.921.891.851.841.721.932.332.11.3
4.56.27.312.98.15.1533.5514.4504.2655.9659.31595.19592.08591.37589.59597.05596.49592.31587.76582.69580.33
1612.117.926.621.733.3818.1737.2807.4848.1781.77684.02655.69692.44652.12733.6744.72662.14669.42669.15784.68
                                         
0.020.020.030.050.050.070.510.50.60.640.710.770.830.890.911.051.161.171.251.311.51
000000000000000000000
-1.2-6.5-14.3-24.5-29.6-42.4651.4-44.5-116.2-203.22-203.09-274.98-304.22-389.96-463.43-541.75-628.02-706.47-788.95-871.43
0000.800.4-23.5-7.722.416.9-37.98-38.69-38.37-39.28-39.41-38.27-0.22-39.7-40.27-40.22-39.06
00000000000-334-3032117-429-39,791-542-543-1,286-912
14.68.817.525.220.831.9552.8490575.8539.2467.99528.16516.77546.01481.05549.33581.4497.04501.84480.36597.44
0.21.70.41.40.91.23.311.81919.528.2427.1621.8118.9213.0624.9719.623.0820.157.0719.08
000.20.100.10.70.40.54.602.023.814.364.235.754.23.332.017.446.23
1.51.6000029.133.326.816.120.170.2411.050.7213.0323.4514.5216.769.8142.2520.48
000000000000000000000
0000000000000014.0135.9755.978.210.0116.4956.84
1.73.30.61.50.91.333.145.546.340.248.4129.4236.672444.3390.1494.2751.3741.9873.24102.63
000000000000059.467.2863.3449.5398.7106.48102.4471.32
000000137136133.4149.5149.3962.6949.2920.0811.120.7300000
00000095.265.751.9119.1115.9963.7552.9642.9648.3330.0619.5215.0219.1113.1213.29
000000232.2201.7185.3268.6265.37126.44102.25122.43126.7394.1369.05113.73125.6115.5684.62
1.73.30.61.50.91.3265.3247.2231.6308.8313.78155.86138.92146.44171.06184.28163.32165.1167.58188.8187.24
16.312.118.126.721.733.2818.1737.2807.4848781.77684.02655.69692.44652.12733.6744.72662.14669.42669.15784.68
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Mesoblast provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Mesoblast's financial health and stability.

Assets

Mesoblast's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Mesoblast must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Mesoblast after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Mesoblast's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES ()
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
2005200620072008200920102011201220132014201520162017201820192020202120222023
0000000000000000-98-91-81
0000000000000000444
0000000000000000000
020000128010205951033276109
000000000000000021616
00000000000000-40000
0000000-732000000000
0-2-7-5-6-8106-74-55-75-101-87-95-75-57-50-100-65-63
0000000-2-2-1-20000-2-100
-3-3-2-40045-5-37-5-10-1-1-3-100
-3-3-2-40058-2-35-2-1000-1000
0000000000000000000
00000000000003143-1-2-6-2
1701312823125517924668614030144119888
1501312822124517324562606871131108-974
-1.00-----1.00---5.00---6.00-1.00-3.00-2.00-12.00-7.00-11.00-11.00
0000000000000000000
10-9-4-3-55205-12543-206-181-126-135-92-731-99-152-61
-0.5-2.4-7.2-5.6-6.9-8.6106.2-77.2-58.4-76.8-103.24-88.72-95.78-75.21-58.07-52.51-102.4-65.94-63.53
0000000000000000000

Mesoblast stock margins

The Mesoblast margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Mesoblast. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Mesoblast.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Mesoblast's sales revenue. A higher gross margin percentage indicates that the Mesoblast retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Mesoblast's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Mesoblast's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Mesoblast's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Mesoblast. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Mesoblast's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Mesoblast Margin History

Mesoblast Gross marginMesoblast Profit marginMesoblast EBIT marginMesoblast Profit margin
2031e70.17 %0 %0 %
2030e70.17 %47.33 %0 %
2029e70.17 %37.54 %0 %
2028e70.17 %63.16 %120.19 %
2027e70.17 %25.39 %-17.08 %
2026e70.17 %-54.04 %-371.36 %
202570.17 %-478.51 %-593.92 %
2024-166.3 %-1,133.28 %-1,490.27 %
2023-269.72 %-836.2 %-1,091.71 %
2022-201.13 %-722.17 %-894.33 %
2021-338.83 %-1,212.27 %-1,325.25 %
202021.29 %-228.55 %-242.38 %
20198.16 %-517.08 %-537.01 %
201868.24 %-370.85 %-203.51 %
2017-400.21 %-3,738.47 %-3,184.7 %
201630.05 %-43.4 %-9.7 %
2015-20.35 %-464.52 %-487.04 %
2014-6.25 %-284.61 %-311.58 %
201327.24 %-208.67 %-214.19 %
201242.3 %-127.71 %-186.48 %
201170.17 %-41.02 %470.56 %
201070.17 %-1,384.85 %-1,971.21 %
200970.17 %-1,066.15 %-1,389.23 %
200870.17 %-876.54 %-1,111.11 %
200770.17 %-416.67 %-518.94 %
200670.17 %-222.75 %-293.84 %

Mesoblast Stock Sales Revenue, EBIT, Earnings per Share

The Mesoblast earnings per share therefore indicates how much revenue Mesoblast has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Mesoblast earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Mesoblast's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Mesoblast’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Mesoblast's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Mesoblast Revenue, EBIT and net profit per share

DateMesoblast Sales per ShareMesoblast EBIT per shareMesoblast Earnings per Share
2031e1.09 undefined0 undefined0 undefined
2030e0.67 undefined0 undefined0 undefined
2029e0.42 undefined0 undefined0 undefined
2028e0.29 undefined0 undefined0.35 undefined
2027e0.15 undefined0 undefined-0.03 undefined
2026e0.06 undefined0 undefined-0.21 undefined
20250.01 undefined-0.07 undefined-0.08 undefined
20240.01 undefined-0.07 undefined-0.09 undefined
20230.01 undefined-0.08 undefined-0.11 undefined
20220.01 undefined-0.11 undefined-0.13 undefined
20210.01 undefined-0.14 undefined-0.15 undefined
20200.06 undefined-0.14 undefined-0.15 undefined
20190.03 undefined-0.17 undefined-0.18 undefined
20180.04 undefined-0.14 undefined-0.08 undefined
20170.01 undefined-0.23 undefined-0.19 undefined
20160.12 undefined-0.05 undefined-0.01 undefined
20150.06 undefined-0.28 undefined-0.3 undefined
20140.07 undefined-0.21 undefined-0.23 undefined
20130.1 undefined-0.21 undefined-0.21 undefined
20120.14 undefined-0.18 undefined-0.26 undefined
20110.08 undefined-0.03 undefined0.39 undefined
20100 undefined-0.06 undefined-0.09 undefined
20090.01 undefined-0.06 undefined-0.07 undefined
20080.01 undefined-0.06 undefined-0.08 undefined
20070.01 undefined-0.05 undefined-0.06 undefined
20060.02 undefined-0.05 undefined-0.07 undefined

Mesoblast business model

Mesoblast Ltd is an Australian biotechnology company specializing in the development and production of novel cell-based therapies for serious diseases. The company was founded in 2004 as a spin-off of the Australian Monash University. Mesoblast's business model is based on the development of cell-based therapies using mesenchymal stem cells (MSCs). The company has specialized in researching MSCs and holds patents for their use in various medical fields. Mesoblast has developed an innovative technology platform to produce MSCs on a large scale and ensure high activity and quality of their products. Mesoblast has three different divisions covering different areas of medicine. The first division focuses on cardiovascular diseases and researches MSC-based therapies for patients with heart conditions such as heart attack or heart failure. The company has already conducted clinical trials with positive results. The second division focuses on orthopedics and spine, aiming to improve the regeneration of poorly healing bone fractures or chronic back problems. Mesoblast has also conducted clinical trials in this area with positive results. The third division focuses on immunology and inflammation, aiming to develop therapeutic applications that regulate inflammatory reactions in the body. These therapies could be used, for example, in autoimmune diseases. Mesoblast offers various products based on the use of MSCs. One of the main products is Temcell, a therapy used to treat graft-versus-host disease (GvHD). GvHD is a life-threatening complication that can occur after a stem cell transplant. Temcell aims to modulate the patient's immune system and alleviate the symptoms of GvHD. Another product of Mesoblast is Revascor, an intravenous infusion used to treat patients with severe heart failure. Revascor contains live MSCs that are intended to promote heart muscle regeneration and improve heart function. Mesoblast is an innovative company specializing in the development of cell-based therapies. The company has already achieved notable successes and is expected to continue bringing groundbreaking products to the market in the future. Mesoblast is one of the most popular companies on Eulerpool.com.

Mesoblast SWOT Analysis

Strengths

Mesoblast Ltd has a diverse portfolio of cell therapy products in various stages of development.

The company has a strong intellectual property portfolio, providing a competitive advantage.

Mesoblast has established partnerships and collaborations with reputable pharmaceutical companies.

Weaknesses

Mesoblast faces challenges in successfully commercializing its cell therapy products.

The company relies heavily on the success of its clinical trials, which pose inherent risks.

There is a dependence on external funding sources to support ongoing research and development.

Opportunities

The growing demand for innovative cell-based therapies presents significant market opportunities for Mesoblast.

Expansion into new geographic regions can help Mesoblast tap into underserved markets.

The increasing prevalence of chronic diseases provides a target patient population for Mesoblast's products.

Threats

Competition from other companies in the cell therapy space poses a threat to Mesoblast's market share.

Regulatory constraints and evolving regulations may impact the company's ability to gain necessary approvals for its products.

Changes in reimbursement policies and healthcare systems could affect the affordability and accessibility of Mesoblast's therapies.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Mesoblast Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Mesoblast historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Mesoblast shares outstanding

The number of shares was Mesoblast in 2024 — This indicates how many shares 986.703 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Mesoblast earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Mesoblast's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Mesoblast’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Mesoblast's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Mesoblast.

Mesoblast latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2023-0.13 -0.03  (78.79 %)2023 Q4
3/31/2023-0.05 -0.02  (50.52 %)2023 Q3
12/31/2022-0.06 -0.03  (48.11 %)2023 Q2
9/30/2022-0.05 -0.02  (52.51 %)2023 Q1
6/30/2022-0.05 -0.03  (34.65 %)2022 Q4
3/31/2022-0.04 -0.03  (18.32 %)2022 Q3
12/31/2021-0.05 -0.04  (20.79 %)2022 Q2
6/30/2021-0.03 -0.08  (-192.78 %)2021 Q4
12/31/20200 -0.09  (0 %)2021 Q2
12/31/2015-0.22 -0.1  (54.45 %)2016 Q2
1
2

Eulerpool ESG Scorecard© for the Mesoblast stock

Eulerpool World ESG Rating (EESG©)

57/ 100

🌱 Environment

58

👫 Social

99

🏛️ Governance

15

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees52
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Mesoblast shareholders

%
Name
Stocks
Change
Date
10.62212 % George (Gregory)128,293,28519,981,9402/4/2025
8.54473 % G to the Fourth Investments LLC103,202,71316,794,7392/4/2025
6.53745 % Itescu (Silviu)78,958,92804/1/2025
5.25366 % The Vanguard Group, Inc.63,453,37629,021,5586/12/2025
3.92323 % State Street Global Advisors Australia Ltd.47,384,445703,1927/25/2025
3.02616 % M&G Investment Management Ltd.36,549,7765,849,8504/30/2025
1.65591 % Thorney Investment Group20,000,00009/27/2024
1.55819 % Vanguard Investments Australia Ltd.18,819,682-4,8826/30/2025
0.85563 % BlackRock Institutional Trust Company, N.A.10,334,20727,8847/31/2025
0.73035 % Josaka Investments Pty Ltd.8,821,1378,821,1379/27/2024
1
2
3
4
5
...
8

Mesoblast Executives and Management Board

Dr. Silviu Itescu

Mesoblast Chief Executive Officer, Executive Director (since 2004)
Compensation 3.02 M

Dr. Eric Rose

(73)
Mesoblast Executive Director, Chief Medical Officer (since 2013)
Compensation 2.29 M

Mr. Philip Krause

Mesoblast Non-Executive Independent Director
Compensation 515,271

Mrs. Jane Bell

Mesoblast Non-Executive Independent Chairman of the Board
Compensation 230,424

Mr. William Burns

(77)
Mesoblast Non-Executive Independent Vice Chairman of the Board (since 2014)
Compensation 200,974
1
2
3

Most common questions regarding Mesoblast

What values and corporate philosophy does Mesoblast represent?

Mesoblast Ltd represents values of innovation, integrity, and collaboration in the field of regenerative medicine. The company aims to develop and commercialize cell-based therapies that have the potential to improve patients' lives. With a focus on advanced manufacturing and rigorous clinical trials, Mesoblast is committed to delivering safe and effective treatments for a variety of conditions, including cardiovascular diseases, orthopedic disorders, and immune-mediated inflammatory diseases. By collaborating with leading research institutions and pharmaceutical partners, Mesoblast strives to be at the forefront of scientific advancements and bring innovative therapies to the market.

In which countries and regions is Mesoblast primarily present?

Mesoblast Ltd is primarily present in multiple countries and regions worldwide. The company's global presence extends to various key markets, including the United States, Japan, Australia, and Europe. With a robust international footprint, Mesoblast Ltd has established itself as a leading biopharmaceutical company, dedicated to innovative cellular medicines.

What significant milestones has the company Mesoblast achieved?

Mesoblast Ltd, a leading biopharmaceutical company, has achieved several significant milestones. Notably, the company successfully completed a Phase 3 pivotal trial for its flagship product, remestemcel-L, in the treatment of graft-versus-host disease (GVHD). Mesoblast also received fast track designation from the U.S. FDA for this potential groundbreaking therapy. Additionally, the company forged strategic partnerships with major pharmaceutical companies, including JCR Pharmaceuticals and Grünenthal, to expand its product pipeline and accelerate commercialization efforts. Mesoblast's groundbreaking research and development efforts, along with its partnerships and successful clinical trials, demonstrate its commitment to revolutionizing the treatment of various diseases and solidify its position as an innovative leader in the healthcare industry.

What is the history and background of the company Mesoblast?

Mesoblast Ltd is a renowned biopharmaceutical company specializing in the development of innovative cellular medicines. Founded in 2004, Mesoblast has excelled in the field of regenerative medicine, aiming to provide effective treatments for challenging inflammatory ailments. With a focus on harnessing the unique regenerative properties of cells, Mesoblast has successfully developed a diverse pipeline of potential therapies. The company has made significant strides in areas such as cardiovascular conditions, orthopedic disorders, and immune-mediated diseases. Mesoblast's dedication to innovation and scientific excellence has positioned it as a global leader in the field of cellular medicines.

Who are the main competitors of Mesoblast in the market?

Some of the main competitors of Mesoblast Ltd in the market are Novartis AG, Johnson & Johnson, Pfizer Inc., and Athersys Inc.

In which industries is Mesoblast primarily active?

Mesoblast Ltd is primarily active in the biotechnology and regenerative medicine industries.

What is the business model of Mesoblast?

The business model of Mesoblast Ltd revolves around developing and commercializing innovative cellular medicines. As a leading global biopharmaceutical company, Mesoblast focuses on leveraging its proprietary allogeneic cell therapy platform to address significant unmet medical needs. By harnessing the power of mesenchymal lineage adult stem cells, Mesoblast aims to deliver effective treatments across a broad range of inflammatory and immune-mediated diseases, cardiovascular conditions, and orthopedic disorders. This commitment to pioneering research and development, coupled with strategic collaborations and a strong intellectual property portfolio, enables Mesoblast to transform the lives of patients worldwide through the potential of regenerative medicine.

What is the P/E ratio of Mesoblast 2025?

The Mesoblast P/E ratio is -18.9.

What is the P/S ratio of Mesoblast 2025?

The Mesoblast P/S ratio is 112.23.

What is the Quality Investing of Mesoblast?

The Quality Investing for Mesoblast is 3/10.

What is the revenue of Mesoblast 2025?

The Mesoblast revenue is 17.2 M USD.

How high is the profit of Mesoblast 2025?

The Mesoblast profit is -102.14 M USD.

What is the business model of Mesoblast

Mesoblast Ltd is an Australian biotechnology company specializing in the development of cellular and regenerative therapies. The company's business model focuses on utilizing its proprietary Mesenchymal Stem Cell technology platform to develop novel therapies for serious medical conditions. The company has three main divisions: Cardiovascular Diseases, Inflammatory Diseases, and Oncology, each responsible for the development of specific treatments. Mesoblast works closely with the academic community and the biopharmaceutical industry to validate its technology platform and bring its products to market. Mesoblast's product range includes Mesenchymal Stem Cell therapies for various indications. Currently, Mesoblast's product portfolio is still in clinical development, but the company has already achieved some important milestones. The Cardiovascular Diseases division is responsible for the development of mesenchymal stem cell therapies for the treatment of cardiovascular diseases. The company has already completed a Phase 3 clinical trial for its heart failure therapy, which has shown promising results. Additionally, Mesoblast's Chronic Heart Failure therapy is currently in clinical trials. The Inflammatory Diseases division includes anti-inflammatory stem cell therapies for the treatment of inflammatory diseases such as rheumatoid arthritis and graft-versus-host disease (GvHD). Mesoblast's GvHD therapy has already received approval from the US Food and Drug Administration and is currently available on the market. The Oncology division is responsible for the development of mesenchymal stem cell therapies for the treatment of cancer. Mesoblast's technology platform allows for targeting a wide range of cancer cells, and the company has already achieved positive results in a Phase 2 clinical trial with a cancer therapy. Another important area of business for Mesoblast is partnerships with other pharmaceutical and biotechnology companies. Mesoblast recently signed an agreement with Novartis to distribute its Hematopoietic Stem Cell Transplantation treatment in the EU region. Additionally, the company is working closely with Tasly Pharmaceuticals to develop a product upgrade for Tasly's prostate cancer medication. Mesoblast's cellular stem cell technology platform forms the foundation for its products and is a significant competitive advantage. Mesenchymal stem cells have the ability to differentiate into various types of cells such as bone, cartilage, adipose tissue, and muscle. Overall, Mesoblast is a company dedicated to the development of innovative cellular and regenerative therapies that have the potential to improve the lives of patients with serious diseases. The company has already achieved important milestones and is working towards bringing its therapies to market, enabling further growth for the company.

What is the Mesoblast dividend?

Mesoblast pays a dividend of 0 USD distributed over payouts per year.

How often does Mesoblast pay dividends?

The dividend cannot currently be calculated for Mesoblast or the company does not pay out a dividend.

What is the Mesoblast ISIN?

The ISIN of Mesoblast is AU000000MSB8.

What is the Mesoblast WKN?

The WKN of Mesoblast is A0DNPW.

What is the Mesoblast ticker?

The ticker of Mesoblast is MSB.AX.

How much dividend does Mesoblast pay?

Over the past 12 months, Mesoblast paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mesoblast is expected to pay a dividend of 0 USD.

What is the dividend yield of Mesoblast?

The current dividend yield of Mesoblast is .

When does Mesoblast pay dividends?

Mesoblast pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mesoblast?

Mesoblast paid dividends every year for the past 0 years.

What is the dividend of Mesoblast?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Mesoblast located?

Mesoblast is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mesoblast kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mesoblast from 9/30/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2025.

When did Mesoblast pay the last dividend?

The last dividend was paid out on 9/30/2025.

What was the dividend of Mesoblast in the year 2024?

In the year 2024, Mesoblast distributed 0 USD as dividends.

In which currency does Mesoblast pay out the dividend?

The dividends of Mesoblast are distributed in USD.

All fundamentals about Mesoblast

Our stock analysis for Mesoblast Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mesoblast Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.